- Oncolytics Biotech Inc. (ONC) announced its China-based partner reported the results of its pelareorep-paclitaxel combination therapy for advanced breast cancer
- The studied combination has been well tolerated, with no dose-limiting toxicities or serious adverse events reported to date
- Disease control, partial response, or stable disease was achieved in 93 per cent of patients
- 86 per cent of which showed tumour shrinkage activity
- One patient achieved a partial at week eight, maintained the response until week 48, and remained on the study
- Oncolytics BiotechInc. (ONC) is down 1.28 per cent and is trading at $2.32 per share as of 2:15 p.m. EST
Oncolytics Biotech (ONC) partner, Adlai Nortye, reported results from a clinical evaluation of pelareorep-paclitaxel combination therapy for advanced breast cancer.
The studied combination has been well tolerated, with no dose-limiting toxicities or serious adverse events reported to date.
Fifteen patients were treated in the trial, with fourteen having had at least one post-baseline tumour assessment. All patients enrolled in the trial were previously treated with at least one endocrine therapy and no more than one line of chemotherapy for recurrent or metastatic disease.
Disease control, partial response, or stable disease was achieved in thirteen of the patients, twelve of which showed tumour shrinkage from baseline.
Seven of fourteen evaluable patients achieved a partial response to the therapy. One patient who achieved a partial at week eight maintained the response until week 48 and remained on the study.
Data from the trial is expected to fast-track Adlai Nortye’s development of pelareorep in China by allowing future regulatory submissions to include data from Oncolytics’ North American metastatic breast cancer trials, IND-213 and BRACELET-1.
Oncolytics expects to report the overall response rate, PFS, and evolving overall survival data from the ongoing BRACELET-1 trial in the first half of 2023.
Oncolytics BiotechInc. (ONC) is down 1.28 per cent and is trading at $2.32 per share as of 2:15 p.m. EST.
